These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 9573653

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
    Kuo BI, Fung CP, Liu CY.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.
    Hagihara M, Kuti JL, Nicolau DP.
    Diagn Microbiol Infect Dis; 2012 Mar; 72(3):258-62. PubMed ID: 22209563
    [Abstract] [Full Text] [Related]

  • 8. Nephrotoxic and peroxidative potential of meropenem and imipenem/cilastatin in rat and human renal cortical slices and microsomes.
    Yousif T, Pooyeh S, Hannemann J, Baumann J, Tauber R, Baumann K.
    Int J Clin Pharmacol Ther; 1999 Oct; 37(10):475-86. PubMed ID: 10543314
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Carbapenems and monobactams: imipenem, meropenem, and aztreonam.
    Hellinger WC, Brewer NS.
    Mayo Clin Proc; 1999 Apr; 74(4):420-34. PubMed ID: 10221472
    [Abstract] [Full Text] [Related]

  • 11. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
    Rhomberg PR, Jones RN.
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243
    [Abstract] [Full Text] [Related]

  • 12. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.
    Verwaest C, Belgian Multicenter Study Group.
    Clin Microbiol Infect; 2000 Jun; 6(6):294-302. PubMed ID: 11168137
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
    Kuti JL, Florea NR, Nightingale CH, Nicolau DP.
    Pharmacotherapy; 2004 Jan; 24(1):8-15. PubMed ID: 14740783
    [Abstract] [Full Text] [Related]

  • 15. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
    Krause R, Mittermayer H, Feierl G, Allerberger F, Wendelin I, Hirschl A, Reisinger EC.
    Wien Klin Wochenschr; 1999 Jul 30; 111(14):549-54. PubMed ID: 10467641
    [Abstract] [Full Text] [Related]

  • 16. Morphological changes induced by imipenem and meropenem at sub-inhibitory concentrations in Acinetobacter baumannii.
    Bernabeu-Wittel M, García-Curiel A, Pichardo C, Pachón-Ibáñez ME, Jiménez-Mejías ME, Pachón J.
    Clin Microbiol Infect; 2004 Oct 30; 10(10):931-4. PubMed ID: 15373891
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Carbapenems: a potent class of antibiotics.
    Nicolau DP.
    Expert Opin Pharmacother; 2008 Jan 30; 9(1):23-37. PubMed ID: 18076336
    [Abstract] [Full Text] [Related]

  • 20. CW-270033, a novel pyrrolidinyl-thio carbapenem, has potent antimicrobial activity in vitro and in vivo.
    Kim J, Ha JR, Oh SW, Kim HG, Lee JM, Lee DG, Lee SH, Kim JG.
    Biol Pharm Bull; 2007 Mar 30; 30(3):575-9. PubMed ID: 17329859
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.